Download presentation
Presentation is loading. Please wait.
Published byFrederica Leslie Harrison Modified over 5 years ago
1
Clinicopathologic significance of cyclooxygenase-2 overexpression in esophageal squamous cell carcinoma Kuang-Tai Kuo, MD, Kuan-Chih Chow, PhD, Yu-Chung Wu, MD, Chen-Sung Lin, MD, Hao-Wei Wang, MD, Wing-Yin Li, MD, Liang-Shun Wang, MD The Annals of Thoracic Surgery Volume 76, Issue 3, Pages (September 2003) DOI: /S (03)
2
Fig 1 Representative examples of cyclooxygenase (COX)-2 immunohistochemical stains. (A) Negative (0) immunoreactivity in the tumor cells (Tu). The stroma (Str) is also negative. This tumor was categorized as COX-2 low (original magnification, ×200). (B) Strong (3+) immunoreactivity in the Tu. The nontumorous Str is either negative or weakly positive. This tumor was categorized as COX-2 high (original magnification, ×200). The Annals of Thoracic Surgery , DOI: ( /S (03) )
3
Fig 2 Western blot analysis demonstrating cyclooxygenase-2 (COX-2) protein expression in six esophageal squamous cell carcinoma samples (CA-1 to CA-6). The CA-4 corresponded to a 1+ tumor, and the CA-6 corresponded to a 0 tumor. The T denotes tumor and the N denotes normal esophageal squamous epithelium. The M means markers for 58kD and 82kD, and the C means control for COX-2 protein. The Annals of Thoracic Surgery , DOI: ( /S (03) )
4
Fig 3 Survival curves of patients at various tumor stages (p < ). The numbers in parentheses are the patients at risk yearly. The Annals of Thoracic Surgery , DOI: ( /S (03) )
5
Fig 4 Survival curves of patients with or without cyclooxygenase-2 (COX-2) expression (p = 0.43). The numbers in parentheses are the patients at risk yearly. The Annals of Thoracic Surgery , DOI: ( /S (03) )
6
Fig 5 Survival curves of stage IV patients with or without cyclooxygenase-2 (COX-2) overexpression (p = 0.17). The numbers in parentheses are the patients at risk yearly. The Annals of Thoracic Surgery , DOI: ( /S (03) )
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.